BioCentury
ARTICLE | Clinical News

Cinvanti regulatory update

January 12, 2017 10:15 PM UTC

Heron submitted an NDA to FDA for IV Cinvanti to prevent chemotherapy-induced nausea and vomiting (CINV). The company expects a decision in late 2017. Cinvanti is a polysorbate 80-free formulation of ...

BCIQ Company Profiles

Heron Therapeutics Inc.